Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.60 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.60 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.60 |
| ▸ | MAP4K3 | Q8IVH8 | 6/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | GRK5 | P34947 | 1/20 | 0.53 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27812249 | 0.86 | CHRNB2 (0.53) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL30113065 | 0.85 | PIM1 (0.64) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL10040495 | 0.84 | ALK (0.59) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL14320710 | 0.84 | PIM1 (0.54) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL15942449 | 0.84 | MAP4K3 (0.58) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL3126749 | 0.84 | ALK (0.59) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| Hydrochloric Acid SCHEMBL20135201 | 0.83 | ALK (0.58) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL2299419 | 0.82 | CHRNB2 (0.47) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 | |
| SCHEMBL14638436 | 0.81 | ALK (0.65) | CHRNB2CHRNA4MAP4K3IRAK4ALK | |
| SCHEMBL15324788 | 0.81 | IRAK4 (0.52) | CHRNB2CHRNA4CYP1A2CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2731942-B1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2731942-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | Novartis AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| CN-103781776-A | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG | 2014-05-07 | — | — | CN | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | CHRNB2 2185/4885CHRNA4 449/4885CYP1A2 741/4885 |
| US-20080194545-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | ABCB11, FPR1, C5 | CHRNB2 4878/4885CHRNA4 4883/4885CYP1A2 119/4885 |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | WNT1, TNKS1BP1, TNKS | CHRNB2 4550/4885CHRNA4 4726/4885CYP1A2 893/4885 |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | CHRNB2 208/4885CHRNA4 139/4885CYP1A2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.